DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance

Information source: Theravance Biopharma R & D, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Enteral Feeding Intolerance

Intervention: TD-8954 (Drug); Metoclopramide (Drug)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: Theravance Biopharma R & D, Inc.

Summary

This study is being conducted to evaluate the safety, tolerability and early efficacy of IV TD 8954 compared to metoclopramide in critically ill subjects, aged 18 to 85 years, who are admitted to the intensive care require mechanical ventilation, and are intolerant to enteral feeding.

Clinical Details

Official title: A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: To evaluate the safety and tolerability of a single IV dose of TD-8954 in subjects with enteral feeding intolerance (EFI)by measuring AEs and ability to tolerate feeding.

Secondary outcome:

To evaluate the pharmacokinetics (PK) of IV TD-8954 with lab values of Tmax.

To evaluate the pharmacodynamics (PD) of IV TD-8954 in subjects with EFI based on gastric emptying as measured by scintigraphy.

To evaluate the pharmacokinetics (PK) of IV TD-8954 with lab values of AUC.

To evaluate the pharmacokinetics (PK) of IV TD-8954 with lab values of Cmax.

To evaluate the pharmacokinetics (PK) of IV TD-8954 with breath tests

Eligibility

Minimum age: 18 Years. Maximum age: 85 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Intubated, on mechanical ventilation, and anticipated to remain on mechanical

ventilation for 2 days after enrollment into the study

- Receiving enteral feeding and assessed to have developed EFI, as defined by a GRV

measurement ≥250 mL within the 24 hours before randomization Exclusion Criteria:

- History of diabetic or idiopathic gastroparesis

- Screening blood glucose >15 mmol/L (270 mg/dL) while receiving insulin

- Impaired renal function, as defined by estimated glomerular filtration rate (eGFR)

<30 mL/min, as determined by the Cockcraft-Gault formula - Bilirubin concentration in

blood >2 times the upper limit of normal

- ALT or AST >3 times upper limit of normal

- Alkaline phosphatase >2 times upper limit of normal

- Contraindication to enteral feeding

- Opioid or other drug overdose as the primary reason for admission to Intensive Care

Unit (ICU)

- Receipt of a drug that can be used as a gastric prokinetic agent

- Receipt of agents known to directly influence the 5 HT4/acetylcholine prokinetic

mechanism

Locations and Contacts

Royal Adelaide Hospital, Adelaide, South Australia TBD, Australia
Additional Information

Starting date: January 2014
Last updated: December 15, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017